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Introduction
Mediterranean fever is an autosomal recessive disease. Its 
features are intermittent attacks of painful inflammation, 
abdominal pain, fever, and arthritis. Full identification 
of the disease has been possible in the last 50 years. It is 
seen in Turkish, Armenian, Jewish (Arabs, Ashkenazi) 
and Mediterranean region ethnics. Its attacks take from a 
few hours to a few days of symptoms and the recurrence 
takes a few weeks or months. Salehzadeh and colleagues 
reported the first comprehensive Mediterranean fever 
patient in Ardabil region (1).
Diagnosis
The diagnosis of Familial Mediterranean fever (FMF) 
is based on Tel-Hashomer clinical criteria, which is two 
or more major symptoms or one major plus two minor 
symptom. Major and minor Tel-Hashomer clinical criteria 
are presented in Table 1 (2).
Livneh et al. suggested that the diagnostic criteria includes 
typical, incomplete, and supportive. A simplified version 
of it is given in Table 2 (3).
The requirements for the diagnosis of FMF have been 
defined as the presence of: at least one major; or at least 
two minor criteria. Typical attacks must include all the 
following: recurrent (at least three episodes), febrile (rectal 
temperature ≥ 38 °C) and short in duration (12 hours to 3 
days). Incomplete attacks (must be recurrent) are defined 
as differing from typical attacks in one or two features as 
follows: 1) temperature <38 °C, 2) attack duration longer 
or shorter than a typical attack (but no less than six hours 
and no more than seven days), 3) no signs of peritonitis 
during the attacks, 4) localized abdominal attacks, and 
finally 5) arthritis in a location other than the hip, knee 
or ankle.
Mediterranean fever genetic testing can be used to detect 
at least two heterozygote mutations or a homozygous 
mutation that is necessary.
Treatment
Targeted therapy to treat acute attacks, prevent relapses 
and is suppressed by chronic inflammation and prevent 
complications. Unfortunately, the exact evaluation of 
treatment response, such as systemic lupus erythematosus, 
is not available. Mediterranean fever can be diagnosed 
wrongly with many organic and non-organic diseases. 
Also a high incidence of psychosomatic and fibromyalgia 
disease can make diagnosis and treatment more and more 
difficult.
Colchicine has been well-known since 1970 that uses 
its impact with 1 mg per day, if it does not respond to 
treatment it can be raised to 1.5 to 2 mg/day, and it can 
be administered twice a day if is not tolerated as a single 
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dose (4-6).
Studies of resistance to colchicine have been reported in 
5% to 10% (7-9). Hence, if a patient is being treated with 
colchicine, other circumstances should be considered 
too, especially if the patient, has previously received 
treatment for other diseases. Using 40 mg of intravenous 
methylprednisolone (10) in acute phase, alpha interferon, 
IL-1 cytokine antagonist (11), IL1 alpha and IL-1 beta 
blocker (12,13), anti TNF (14) and dapsone (15) is 
reported to be effective.
Complications
Amyloidosis is the most common complication of FMF 
(16), and it determines whether the prognosis of the 
disease is associated with progression to end-stage renal 
disease (10-16). Colchicine prevents the occurrence 
of amyloidosis, to stop amyloidosis, and even regress 
it. The duration of the disease is not the main cause of 
amyloidosis but specific genetic and environmental 
conditions is necessary. Prevalence of amyloidosis in 
Armenians is 24% but about those Armenians living 
in California no amyloidosis has been reported (17). 
Homozygote of M694V is mostly observed in Amyloidosis 
patients (18). End-stage renal disease and nephrotic 
syndrome is the most common finding in amyloidosis. 
Mediterranean fever patients need to be evaluated against 
proteinuria regularly (15-18). Some studies on fat skin 
biopsy for amyloidosis have low sensitivity in evaluations 
(19-21). We have shown that the beneath fat pad skin 
biopsy is valuable and reduces the need for renal biopsy 
(Figure 1) (22). Peritoneal mesothelioma due to chronic 
inflammation has been reported (23). Hip involvement 
is destructive in which ultimately needs to have joint 
replacement (24,25). Ankylosing spondylitis is a form of 
spinal involvement and has no relation with HLA B27 (26-
28). Early atherosclerosis that is similar to some patients 
with rheumatic diseases has been seen. Also, valvular 
Table 1. Tel-Hashomer diagnosis criteria
Major criteria Minor criteria
Recurrent febrile episodes with serositis (peritonitis, synovitis or pleuritis) Recurrent febrile episodes
Amyloidosis of AA type without a predisposing disease Erysipelas-like erythema
Favorable response to regular colchicine treatment FMF in a first-degree relative
Table 2. Simplified FMF diagnosis criteria suggested by Livneh et al.
Major criteria Minor criteria
Typical attacks (1-4) Incomplete attacks involving either or both of the following sites
1- Generalized peritonitis 1- Chest
2- Unilateral pleuritis or pericarditis 2- Joint
3- Monoarthritis (hip, knee, ankle) 3- Exertional leg pain
4- Fever alone 4- favorable response to colchicine
5- Incomplete abdominal attack
involvement particularly aortic is observed (29,30). 
Involvement of conducting system of the heart and 
amyloidosis arthropathy are also other  complications of 
FMF. PAN (31),  Henoch-Schonlein purpura and  Behcet’s 
syndrome (30-33) in FMF patients has high incidence. 
Among our patients the main cause of chronic kidney 
disease was focal segmental glomerulosclerosis (22).
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Figure 1. Approach Renal Involve in FMF  
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